$6.95
+4.98%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.79
From 52W high−23.63%
Volume395554.00
Market cap$459.21M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.79
From 52W high
−23.63%
Volume
395554.00
Market cap
$459.21M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.1x
P/E (TTM)
—
RSI (14)
43.2
MomentumView details →
1D Return
+4.98%
YTD Return
−7.68%
SummaryUpdated Jun 1, 2026
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a clinical-stage biotechnology company founded in 2011 and headquartered in Victoria, Canada. Originally incorporated as Plaza Capital Partners Inc., the company changed its name to Eupraxia Pharmaceuticals in May 2012. The company focuses on developing innovative drug delivery technologies for treating inflammatory conditions and pain management, with its lead programs currently in Phase II and Phase III clinical trials.
Similar companies
Latest newsMore news →
Eupraxia Pharmaceuticals announced updated 52-week clinical data from the highest dose cohort of its Phase 1b/2a RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis, highlighting long duration of response, high remission rates and tolerability.19d agoEupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis patients, showing reductions in odynophagia and dysphagia severity through 52 weeks post treatment.67d agoEupraxia Pharmaceuticals presented new data at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI.69d ago